Axcynsis Therapeutics Receives FDA Clearance for IND Application of AT03-65, a Differentiated CLDN6-Targeting ADC, Powered by AxcynDOT™ Technology
Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...
Korea Joongang Daily on MSN14h
Ulcerative colitis drug Zymfentra to generate fifth of Celltrion's 2025 revenue
Celltrion plans to generate 20 percent of its annual revenue this year from its original drug Zymfentra as part of its ...
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development ...